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Neonatal abstinence syndrome (NAS) refers to the constellation of signs and 
symptoms exhibited by a newborn of drug-abusing mother. NAS is multisystemic 
disorder, most frequently involving central nervous and gastrointestinal systems with 
irritability, high-pitched cry, hyperactive reflexes, increased muscle tone, tremors, 
generalized convulsions, feeding and sleeping disorders, tachycardia, tachypnea, 
apnea, termolability and sweating, frequent hiccups, yawning and sneezing, vomiting, 
diarrhea and dehydration. 
Intrauterine narcotic disposition can give some other adverse effects beside NAS: 
fetal distress, premature birth, intrauterine growth retardation, microcephaly, 
increased incidence of congenital anomalies (cardiac and genitourinary anomalies, cleft 
palate, biliar atresia). Significantly increased risks of sudden infant’s death syndrome 
(SIDS), abnormalities in neurocognitive and behavioral development and deficiency in 
motor functions have also been noticed after the long-term surveys of these children. 
This paper is a case report of a newborn with developed clinical signs of NAS, but it 
also discusses diagnostics and management of such cases Acta Medica Medianae 
2008;47(1):55-59. 
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Introduction 
 
Neonatal abstinence syndrome (NAS) 
refers to the constellation of signs and symptoms 
exhibited by newborn of drug-abusing mother (1). 
Practically, every drug used during pregnancy 
can transfer across the placenta and accumulate 
in the fetus and amniotic fluid (2). Most of these 
substances either bind to various central nervous 
system (CNS) receptors or affect the release and 
reuptake of various neurotransmitters (2), so the 
fetus too can develop drug dependence. At 
delivery, transplacental drug transfer ceases 
while neonatal drug metabolism and excretion 
continue, leading to drug disappearance and, 
consequently, manifestations of neonatal "wit-
hdrawal" or "abstinence" (3). Incidence of NAS is 
directly proportional to number of drug  abusers 
in the overall population, and that number is 
constantly increasing in modern society. At least, 
one quarter of drug abusers are women, almost 
all in fertile age (4). Based on the National 
Survey on Drug Use and Health in the United 
States in 2003, the prevalence of illicit drug use 
among Americans is 8.2%, and, among pregnant 
females aged 15-44 years, the prevalence is 
4,3%. Marijuana is the most common illicit drug 
used (1). According to Europe Agency for 
Reconstruction survey about drug abuse, there is 
approximately 100000 drug- abusers in Serbia, 
and almost 11% of Serbian population have tried 
at least once some  of the illicit narcotics, most 
frequently marijuana. NAS occurs in 60% of all 
fetuses exposed to drugs (5), that is in 55-94% 
cases of newborns prenatally exposed to opiates 
or heroin (6). The incidence of NAS is hard to 
obtain because of very unreliable data of prenatal 
drug exposure and limited diagnostic tools. 
The aim of this paper was to point out dia-
gnostic procedures and management of abstine-
nce syndrome in newborns. 
 
Case report 
 
A boy suffering from NAS was born at the 
Clinic of Gynecology and Obstetrics in Novi Sad in 
January 2, 2006. According to anamnesis data 
obtained from the boy’s mother, it was her first 
pregnancy, regularly controlled. The mother was 
on oral Fe medication because of anemia. Trough 
whole pregnancy, she smoked a pack of cigare-
ttes per day. Her gynecologist advised her to N e o n a t a l   a b s t i n e n c e   s y n d r o m e                 A l e k s a n d r a   M a t i ć 
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perform HIV and hepatitis test, which both were 
negative. Two days before delivery, the mother 
consumed marijuana; on questions about previous 
drug abuse, or other substances and alcohol, 
besides marijuana, she gave negative answers. 
Mother was born in 1978, finished high school, 
worked as croupier in local casino until she had 
found out about her pregnancy. She lived with 
the boy’s father, but they were not married. 
Data obtained from the boy’s father pointed 
to regular intravenous narcotic abuse by boy’s 
father and mother’s sister; they also claimed that 
the boy’s mother was drug abuser, too. 
The delivery was preterm, in 36 4/7 gesta-
tional weeks, started with labor pains. Amniotomy 
was performed, with green meconial amniotic 
fluid. The child’s Apgar score was 10/10, birth 
weight 2920 g, birth length 46 cm, head circumfe-
rence 34 cm (eutrophic parameters). In the first 
5 days, the newborn was treated in the Nursery 
Ward in the Clinic of Gynecology and Obstetrics, 
than transported to our Institute with the following 
diagnosis: Neonatus praetemporarius masculinus 
eutrophicus. Fetal distress. Respiratorius distress. 
Iritabilitate cerebri. Fractura claviculae. 
On admittance, the newborn was 5 days old, 
rectal temperature 37,7°C, with icteric skin with few 
petechiae in abdominal region. Slightly lower, skin 
turgor. Excessive cry, periodically high pitched. 
Severe tremor after tactil stimulation, mild sponta-
neous tremor. Occasionally, the presence of slurping 
movement. Tachypnea – respirations 68/min. 
Increased axial and segment muscle tone, as well 
as Moro reflex. All these findings were present with 
phenobarbital treatment, started in the Clinic of 
Gynecology and Obstetrics.   
The infant was placed in a separate dar-
kened room. Feedings every 2–3 hours, adapted 
premature infants formula; meals well tolerated. 
Because of the presence of clinical findings 
consistent with NAS, drug treatment with Pheno-
barbital proceeded in the same dosage (20 mg/kg); 
repeated everyday scoring using the modified 
version of a scale developed by Finnegan was 
performed. On the first day of admittance, the 
score was between 12 and 15, with gradual 
decreasing during the following  days. The signs of 
hyperreactivity of central nervous system domi-
nated in clinical findings, with practically normal 
gastrointestinal functions. Parallel with withdrawal 
of signs of NAS, the Phenobarbital therapy was 
gradually reduced until discontinuation. There was 
no clinical aggra-vation during the period of 
reducing Phenobarbital, as well as 48 hours after 
Phenobarbital disconti-nuation. In the last couple of 
days of hospital stay, all infant’s discomforts were 
completely withdrawn. 
Appropriate laboratory and microbiology 
tests showed no presence of hypoglycemia, 
hypocalcemia, neonatal sepsis. HIV and hepatitis 
tests were negative. 
Mother was not with the infant during intrahos-
pital management, but regularly visited her child.  
Discussion 
 
Drugs most often connected with NAS are 
opiates, cocaine and his derivatives, ampheta-
mine (speed) and alcohol (7). Drugs frequently 
associated with neonatal problems include also 
the following: barbiturates, caffeine, chlordiaze-
poxide, diazepam and lorazepam, diphenhy-
dramine, marijuana, phencyclidine. Neonatal 
nicotine abstinence syndrome is also described 
(8,9). Maternal polydrug use has been reported 
to result in more frequent and more severe 
neonatal withdrawal signs than single drug use 
(3). Besides drugs themselves, lifestyle and 
behavioral habits of drug-abusing women have 
also adverse effects on pregnancy outcome: 
sexual transmitted diseases, malnutrition, poor 
prenatal care (10). 
Although the full spectrum of physical 
damage that drugs of abuse can cause is not 
documentable, one thing is certain: the effect of 
maternal drug use on fetal brain development is 
the most critical and most studied effect. 
Continuous abuse, especially during the first half 
of gestation, is likely to disrupt the complicated 
neural wiring and associative connections that 
allow the developing brain to learn and mature (5). 
Intrauterine narcotic dispossure can give 
some other adverse effects beside NAS: fetal 
distress, premature birth, intrauterine growth 
retardation, microcephaly, increased incidence of 
congenital anomalies (cardiac and genitourinary 
anomalies, cleft palate, biliar atresia).  
Manifestations of NAS depend on various 
factors, including the drug used, its dose, 
frequency of use, infant's last intrauterine drug 
exposure and mother's and the infant's own 
metabolism and excretion of the active compo-
und or compounds (1). The onset of narcotic 
withdrawal, is frequently during the first 48 to 72 
hours, but may be delayed as late as 4 weeks. 
Subacute signs of narcotic drug withdrawal may 
last up to 6 months. (6). NAS is multisystemic 
disorder, most frequently involving central nervo-
us and gastrointestinal system with irritability, 
high-pitched cry, hyperactive reflexes, increased 
muscle tone, tremors, generalized convulsions, 
feeding and sleeping disorders, tachycardia, 
tachypnea, apnea, termolability and sweating, 
increased hiccups, yawning and sneezing, 
vomiting, diarrhea and dehydration. 
Intrauterine cocaine exposure has also been 
associated with an increased risk of necrotizing 
enterocolitis and central nervous system stroke 
or hemorrhage (11). 
Long-term follow-up of intrauterine drug - 
exposure is not easy to estimate having in mind the 
potential for difficult social situations, such as 
increased risk for child abuse and neglect (11,16). 
Nevertheless, significantly increased risk of sudden 
infant’s death syndrome (SIDS) (1,11), abnorma-
lities in neurocognitive and behavioral development 
(11,17) and deficiency in motor functions (16) have Acta Medica Medianae 2008,Vol.47               Neonatal abstinence syndrome 
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been confirmed in these children by several studies. 
In a small study, developmental scores on the 
mental index on the Bayley Scales of Infant 
Development were not affected by severity of 
withdrawal or the treatment chosen (6). 
Diagnosis of NAS is not easy to obtain. 
Maternal history of drug use is often unreliable. 
Few studies showed that 24–63% of mothers 
with positive cocaine tests deny cocaine use (11). 
Even if the mother does admit to substance abuse, 
the accuracy of the recall about frequency of use, 
range of drugs used including alcohol and nicotine, 
is often poor. Clinical diagnosis is complicated by 
the fact that some drug-exposed infants do not have 
immediate or specifically recognizable symptoms in 
the newborn period. Differentiating neonatal signs 
of drug withdrawal from irritability of the CNS 
resulting from infectious or metabolic disorders, 
such as hypoglycemia and hypocalcemia, may be 
difficult; no clinical signs should be attributed solely 
to drug withdrawal without appropriate assessment 
and diagnostic tests to rule out other causes (6). 
So, the foundation of NAS diagnosis is a 
combination of maternal history, newborn clinical 
symptoms, and laboratory toxicological testing of 
the mother and newborn (11). 
Indicators of increased risk for intrauterine 
drug exposure of a newborn are (6,11): 
1.Maternal characteristics: history of drug abuse in 
present or previous pregnancies, history of drug 
– abusing partner, homelessness, severe mood 
swings, previous unexplained fetal demise, 
cerebrovascular accidents, no or poor prenatal 
care, history of hepatitis B, AIDS, syphilis, 
gonorrhea, prostitution, precipitous labor, 
abruptio placentae, unexplained preterm labor. 
2.Infant characteristics: prematurity, unexplained 
intrauterine growth retardation, neurobehavioral 
abnormalities, atypical vascular incidents, such 
as cerebrovascular accidents and necrotizing 
enterocolitis in otherwise healthy full-term 
infants, unexplained convulsions or apnee, signs 
and symptoms that correlate with NAS 
(hypertonia, irritability, convulsions, tremors, 
muscular rigidity, diarrhea). 
In case of strong suspicion of NAS, 
consider toxic screening: 
1.Urine screening of the newborn – most widely 
used; will have a high a false-negative rate 
because only results for infants with recent 
exposure will be positive (6). 
2.Meconium drug testing - although not 
conclusive if results are negative, is more likely 
to identify infants of drug-abusing mothers 
than is infant urine testing (6); more expensive 
and less available testing (1) 
3.hair analyses – expensive method available only 
in largest centers; drug metabolites can be 
detected in infant hair for 2-3 months after 
birth (1), but recent exposure can be missed 
because of slow hair growth. 
If the mother is an intravenous drug abuser, 
screen for HIV, hepatitis B and C, Chlamydia, 
syphilis, and gonorrhea (1,5). 
Social services should be alarmed because 
of many legal – social issues of this situation (11). 
Treatment of a newborn suffering from 
NAS consists of: 
1.Supportive care, 
2.Drug treatment. 
The best and most widely used scale to 
evaluate the neonate for NAS is the modified 
version of a scale developed by Finnegan, which 
we also used in our case. Using 16 items, it 
allows a semiquantitative measure of the degree 
to which the newborn is experiencing symptoms 
of withdrawal. This scale can also be used to 
assess the resolution of signs and symptoms after 
initiating treatment (1). An infant of a drug – 
abusing mother should be scored 2 hours after 
birth or even earlier, if there is evidence of NAS 
signs, and measurements should be performed 
every 2-4 hours (1/2–1 hour after feeding) (2,5). 
In the case of finding three consecutive scorings 
equal to or greater than 8, drug treatment for 
withdrawal is indicated (1,2,5).  
Initial treatment of the neonate expe-
riencing drug withdrawal should be primarily 
supportive, because pharmacologic therapy subject 
the infant to exposure to drugs and may prolong 
hospitalization (6). Supportive care includes resi-
dence in darkened room to decrease sensory 
stimulation and irritability, frequent small fee-
dings of hypercaloric formula to supply the additi-
onal caloric requirements, and observation of 
sleeping habits, temperature stability, weight gain 
or loss, or change in clinical status that might 
suggest another disease process (4,6). Gentle 
swaddling with positioning that encourages 
flexion and prevention of excessive crying with a 
pacifier is advisable (2). Supportive care in the 
form of intravenous fluids and replacement 
electrolytes may be necessary to stabilize the 
infant’s condition in the acute phase without the 
need for pharmacologic intervention. The clinical 
signs of many infants who manifest drug 
withdrawal may be treated in this manner (6). 
As was previously stressed, if supportive care 
alone can’t lower clinical scores in three consecutive 
scorings under 8, a drug treatment is indicated. 
Pharmacologic therapy of withdrawal-associated 
seizures is indicated; other causes of neonatal 
seizures must be evaluated ae well. Vomiting, 
diarrhea, or both, associated with dehydration and 
poor weight gain, in the absence of other diagno-
ses, are relative indications for treatment, even in 
the absence of high total withdrawal scores (6). 
Most widely used are morphin preparates (pareg-
oric, tincture of opium) and Phenobarbital, less 
often chlorpromazine, clonidine, diazepam (2). 
Combination therapy is sometime applied – 
morphine and Phenobarbital, especially when poly-
drug and alcohol use are suspected. The general 
aim of treatment is to allow sleep and feeding 
patterns to be as close to normal as possible, 
without oversedation of the newborn (2). Naloxone 
administration is an absolute contraindication in the 
resuscitation of a neonate born to a mother who 
used narcotics; use of naloxone, especially if respi-N e o n a t a l   a b s t i n e n c e   s y n d r o m e                 A l e k s a n d r a   M a t i ć 
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ratory depression exists, leads to abrupt withdrawal 
(1,2,3,4,5,6). 
Advise breastfeeding, because it confers, 
among other benefits to the neonate, bonding 
benefits essential to the mother who is drug 
dependent. Breastfeeding is contraindicated if the 
mother is still using illicit drugs or has infections 
such as HIV or hepatitis (1).  
 
Conclusion 
 
It is presumable for neonatal abstinence 
syndrome to become more frequent neonatologist’s 
problem, since narcotic abuse in modern society 
is steadily increasing.  
Diagnosis of NAS is not easy to establish; it 
is necessary to have that possibility in mind, to 
be able to gather and esti-mate all relevant data 
and clinical and laboratory findings. Management 
of NAS should be led by clinical signs and 
symptoms, and supportive care is the basic   
treatment. Any newborn that has been exposed to 
drugs is considered at risk for developmental and 
cognitive compromises; there-fore, these children 
should have regular long- term follow-up to quickly 
identify the potential deficits. 
 
 
 
 
References 
 
1.  Belik J, Hawes J. Neonatal Abstinence Syndrome. E-
medicine. 2006- elektronsko izdanje (http://www. 
emedicine.com/ped/topic2760.htm) 
2.  Gomella TL, Cunningham MD, Eyal FG, Zenk KE 
Neonatology: management, procedures, on-call pro-
blems, diseases and drugs. New York, 2004:424-33. 
3.  Bada H S, Bauer C R, S Shankaran S, B Lester B, L 
L Wright LL,  Das A, et al. Central and autonomic 
system signs with in utero drug exposure. Archives 
of Disease in Childhood Fetal and Neonatal Edition 
2002;87:106-12 
4.  Coghlan D, Milner M, Clarke T, Lambert I, Mcdermot 
C, Mcnally M et al. Neonatal Abstinence Syndrome. 
Irish Medical Journal, 1999; 92 (1): 232-6. 
5.  Wang M. Perinatal Drug Abuse and Neonatal Drug 
Withdrawal. E-medicine. 2004- elektronsko izdanje 
(http://www.emedicine.com/ped/topic2631.htm)  
6.  American Academy of Pediatrics: Neonatal Drug 
Withdrawal. Pediatrics 1998;101(6):1079-88  
7.  Schechner S. Drug abuse and withdrawal. In: 
Cloherty JP, Eichenwald EC, Stark AR, eds. Manual 
of Neonatal Care, Philadelphia. 2004:223-35. 
8.  Garcia-Algar O, Puig C, Mendez C, Vall O, Pacifici 
R, Pichini S. Neonatal nicotine withdrawal syndro-
me. J Epidemiol Community Health 2001;55:687–8 
9.  Slotkin T A. Fetal Nicotine or Cocaine Exposure: 
Which One is Worse? The Journal of Pharmacology 
and Experimental Terapeutics 1998;285(3):931–45.  
10.  Savitz D A, Henderson L, Dole N, Herring A, Wilkins 
D G, Rollins D, Thorp J M Jr. Indicators of Cocaine 
Exposure and Preterm Birth. Obstet Gynecol 
2002;99:458–65. 
11.  Kwong T C, Ryan R M. Detection of intrauterine 
illicit drug exposure by newborn drug testing. 
Clinical Chemistry. 1997;43:235-42. 
12.  Behnke M, Davis Eyler F, Wilson Garvan C, Wobie 
K. The Search for Congenital Malformations in 
Newborns With Fetal Cocaine Exposure. Pediatrics 
2001; 107 (5):74. 
13.  Bada H S, Das A, Bauer C R, Shankaran S, Lester 
B, Wright L L et al. Gestational Cocaine Exposure 
and Intrauterine Growth: Maternal Lifestyle Study. 
Obstetrics & Gynecology 2002;100:916-924. 
14.  Kelly R H, Russo J, Holt V L, Danielsen B H, Zatzick 
D F, Walker E, Katon W. Psychiatric and Substance 
Use Disorders as Risk Factors for Low Birth Weight 
and Preterm Delivery . Obstetrics & Gynecology 
2002;100:297-304. 
15.  Smith L M, LaGasse L L, Derauf C, Grant P, Shah R, 
Arria A et al. The Infant Development, Environment, 
and Lifestyle Study: Effects of Prenatal Metham-
phetamine Exposure, Polydrug Exposure, and 
Poverty on Intrauterine Growth. Pediatrics 2006; 
118:1149-56. 
16.  Arendt R, Angelopoulos J, Ann Salvator A, Singer L. 
Motor Development of Cocaine-exposed Children at 
Age Two Years. Pediatrics 1999; 103 (1): 86-92. 
17.  F r a n k  D  A ,  A u g u s t y n  M ,  G r a n t  K n i g h t  W ,  P e l l  T ,  
Zuckerman B. Growth, Development, and Behavior 
in Early Childhood Following Prenatal Cocaine 
Exposure. JAMA. 2001;285:1613-25. 
 
 
 
 
APSTINENCIJALNI SINDROM NOVOROĐENČETA – PRIKAZ BOLESNIKA 
 
Aleksandra Matić 
 
 
Apstinencijalni sindrom novorođenčeta (neonatal abstinence syndrome – NAS) pred-
stavlja skup simptoma i znakova koje ispoljava novorođenče majke – narkotičnog zavisnika. 
NAS je multisistemski poremećaj, koji najčešće uključuje centralni nervni i gastro-
intestinalni sistem, sa pojavom iritabilnosti, plačem visokog tonaliteta, hiperaktivnim ref-
leksima, povišenim mišićnim tonusom, tremorom, konvulzijama, poremećajima hranjenja i 
spavanja, tahikardije, tahipneje, apneje, termolabilnosti i znojenja, učestalog štucanja, 
zevanja i kijanja, dijareje, povraćanja i dehidracije. 
Osim NAS, narkotici mogu dati i druge vidove oštećenja ploda: fetalni distres, pre-
vremeno rođenje, intrauterini zastoj rasta, mikrocefaliju, povećanu incidencu kongenitalnih 
anomalija (srčane mane, genitourinarne anomalije, rascep nepca, bilijarna atrezija). Acta Medica Medianae 2008,Vol.47               Neonatal abstinence syndrome 
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Takođe je utvrđen signifikantno veći rizik od sindroma iznenadne smrti odojčeta (SIDS), 
abnormalnog neurokognitivnog i bihevioralnog razvoja kao i deficijentnog motornog 
razvoja u ovoj subpopulaciji dece.  
U radu je prikazan slučaj novorođenčeta sa izraženim simptomima i znacima NAS, te 
diskusija o dijagnostikovanju i zbrinjavanju ovakve novorođenčadi. Acta Medica Medianae 
2008;47(1):55-59. 
 
Ključne reči:  apstinencijalni sindrom novorođenčeta, novorođenče, zloupotreba 
narkotika, konvulzije, tremor 
 
  